
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Eli Lilly said it has withdrawn its new drug application for duloxetine hydrochloride for the treatment of stress urinary incontinence.





